Mass photometry pioneers open US headquarters

Mass photometry technologies company Refeyn has celebrated the official opening of its new 10,000 ft² US Headquarters and Customer Interaction Center in Waltham’s Biotech Hub in Greater Boston, Massachusetts. Attended by senior representatives from neighboring biotech companies and Refeyn customers and employees, the event marked a significant milestone in the rapid growth of Refeyn since it was spun out of Oxford University just six years ago.

Company co-founder, Philipp Kukura led the research team that invented mass photometry, a light-based bioanalytical tool for rapid, single-particle analysis. “In the early days, mass photometry’s potential was obvious and the key question wasn’t ‘What can mass photometry do?’ but ‘What can mass photometry not do? It is amazing to witness the opening of Refeyn’s state-of-the-art US HQ today, having started in an early 19th century building above a burger joint in central Oxford, which feels like only yesterday,” he commented.

CEO Gerry Mackay said: “With the opening of our new US HQ, the success of Refeyn and mass photometry is evident as we now have over 180 employees globally and are currently recruiting more to support our expanding US customer-base from our new facility. Furthermore, with over 300 scientific papers to date citing mass photometry, this literature highlights the ever-growing capabilities of this unique technology as it is increasingly adopted in life science laboratories around the world.”

The new HQ enables visiting customers from across North America to run samples and test applications. The company is working to achieve sustainability certification for this laboratory space, which includes a BSL-2 lab, service center, R&D center and applications lab. 

The grand opening followed the successful third annual Mass Photometry Summit 2024 (22 May), where presenters included Dr Di Wu of the National Institutes of Health, an early adopter of mass photometry, who talked about SEC-MP, a technique for AAV characterisation for gene therapy that he and colleagues published in 2023. The Keynote speaker was Professor Priyamvada Acharya from Duke University School of Medicine, whose work focuses on the HIV-1 envelope.

More information online